Translating and Commercialising Genomic Research

This new course aims to develop professional skills to help translate
genomics research into healthcare products and services that ultimately
benefit society.

The rapid progress in genomics research over the past decade has brought
great potential for public benefit. The next generation sequencing era is
helping to develop diagnostic products, new approaches to drug discovery
and development, and stratified medicine approaches to therapy. However,
translation paths for technologies are still emerging. This course will
focus on the specific knowledge required to translate and commercialise
genomics research, for example the type of IP (e.g. database rights,
software copyright vs more ’classical‘ patent rights), the history and
culture landscape (e.g. navigating the complexities of open source
licenses for the benefit of innovation), and the use and sharing of human
genetic data, including ethical and policy considerations.

The programme will be delivered by entrepreneurs, investors, industry
users and technology transfer professionals who will discuss options
through real life examples of the exploitation of databases,
bioinformatics tools, biomarkers, genetic signatures or gene panels. The
content will be delivered through lectures, discussions, case studies and
group work. Together with senior investment professionals and
entrepreneurs, course participants will examine and discuss real life
business models.

This course is designed for a range of professionals involved in
exploitation of technologies, such as business development professionals,
business analysts in the investment community, innovation funders or
senior researchers actively involved in translation. As the course has a
specific emphasis on highlighting business models and developing spin
outs as an exploitation route, it will also be useful to aspiring
entrepreneurs. Through this course we aim to help build a community of
professionals working in the translation of genomics and informatics.

Learning outcomes
After attending this course, participants will be able to:

• Plan an exploitation strategy that considers the impact on future research and on clinical adoption.
• Navigate the regulatory environment that frames the implementation of genomics tools and diagnostics in the clinic.
• Work within the ‘culture landscape’ of software licenses and innovation framework.
• Exploit a variety of business models around biodata, bioinformatics or genomic information.

The course will start at approximately 9.30 on Wednesday, 7 December and
close at approximately 16.00 on Friday, 9 December 2016.

The programme will be delivered by entrepreneurs, investors, industry
users and technology transfer professionals. The content will be
delivered through lectures, discussions, case studies and group work.
Each session will start with an introduction to the the session followed
by discussions of real life examples, relevent case studies and group
work. We aim to provide an immersive and engaging experience for
participants.

Sessions will include:

• Commercial opportunities arising from data aggregation
• Exploiting bioinformatics tools
• Externalising bioinformatics pipelines
• Translating biomarkers, genetic signatures or gene panels

This is a residential course. All participants are requested to stay
onsite for the full duration to benefit fully from discussions and
interactions with the faculty and other students.

Scientific programme committee
Emmanuelle Astoul Wellcome Trust Sanger Institute, UK
Fiona Nielsen
Repositive/DNAdigest, UK
Abel Ureta-Vidal Eagle Genomics, UK
Ross Rounsevell Wellcome Trust Sanger
Institute, UK

Keynote speaker
Phil Stephens Foundation Medicine, USA

Tutors
Melina Cimler Adaptive Biotechnologies, USA

Patrick Farrant Taylor Vinters, UK
Davina Gale Inivata, UK
Emily Hayes Mewburn Ellis, UK
Angus Lauder Cancer Research Technology, UK
Wouter Meuleman Illumina Ventures, USA
Simon Portman Marks and Clerk Solicitors,
UK
David Rainford Taylor Vinters, UK
Sobia Raza PHG Foundation, UK
Frank Schacherer Qiagen, Germany
Simon Turner Kuma Partners, France
Tom
Weaver Congenica, UK

Event organiser
Jane Sullivan Wellcome Genome Campus, UK

Fees

The fees include accommodation, meals and lectures for the duration of
the course. The fee will be requested once acceptance is confirmed.

Accommodation
This is a residential course. All participants will stay at The Wellcome
Genome Campus Conference Centre, Hinxton, Cambridge, for the nights
of 7 and 8 December 2016.

If you wish to book onsite accommodation either side of the course
dates, please contact the Conference
Centre directly.

Applications
Application deadline: Closed

Places on this course are limited. Applicants should be professionals
involved in exploitation of technologies (such as knowledge
transfer/technology transfer professionals), business analysts in the
investment community, innovation funders, senior researchers actively
involved in translation, or aspiring entrepreneurs.

Please note: Applicants should be familiar with the
basics of technology transfer and IP exploitation. Incomplete
applications will not be considered.

The selection process will take place in early November 2016.

Travel visas
Please contact the event organiser if you require a letter to support a
travel visa application. Note that letters will be provided to confirmed
attendees on request.

Non-European Economic Area or Swiss nationals may be required to have a
visa to enter the UK.
Early application is strongly advised, as this process can take 6-8 weeks
or longer.

Please visit the following websites for further information:
UK Border Agency website: www.ukba.homeoffice.gov.uk/visas-immigration/
Information for general visitors and business visitors: www.ukba.homeoffice.gov.uk/visas-immigration/visiting/business/business-activities/

A limited number of registration bursaries are available to attend this
course (up to 50% of the fee).
The following documents will need to be provided:

• CV
• Covering letter

To apply, please contact the event organiser.

Bursary deadline: Closed